167 related articles for article (PubMed ID: 11418461)
21. Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia.
Dimopoulos MA; Hamilos G; Zervas K; Symeonidis A; Kouvatseas G; Roussou P; Gika D; Karmiris T; Bourantas K; Zomas A; Mitsouli C; Xilouri I; Vervessou E; Matsis K; Anagnostopoulos N; Economopoulos T;
Ann Oncol; 2003 Aug; 14(8):1299-305. PubMed ID: 12881396
[TBL] [Abstract][Full Text] [Related]
22. Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia.
Peinert S; Tam CS; Prince HM; Scarlett J; Wolf MM; Januszewicz EH; Westerman D; Seymour JF
Leuk Lymphoma; 2010 Dec; 51(12):2188-97. PubMed ID: 20939696
[TBL] [Abstract][Full Text] [Related]
23. Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders.
Johnson SA; Owen RG; Oscier DG; Leblond V; Levy V; Jaeger U; Seymour JF
Clin Lymphoma; 2005 Mar; 5(4):294-7. PubMed ID: 15794869
[TBL] [Abstract][Full Text] [Related]
24. Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2017 Feb; 92(2):209-217. PubMed ID: 28094456
[TBL] [Abstract][Full Text] [Related]
25. Waldenström's macroglobulinemia.
Desikan KR; Dhodapkar MV; Barlogie B
Curr Treat Options Oncol; 2000 Jun; 1(2):97-103. PubMed ID: 12057047
[TBL] [Abstract][Full Text] [Related]
26. Fludarabine therapy in Waldenström's macroglobulinemia patients treated previously with 2-chlorodeoxyadenosine.
Lewandowski K; Halaburda K; Hellmann A
Leuk Lymphoma; 2002 Feb; 43(2):361-3. PubMed ID: 11999570
[TBL] [Abstract][Full Text] [Related]
27. Fludarabine in Waldenstrom's macroglobulinemia.
Souchet-Compain L; Nguyen S; Choquet S; Leblond V
Expert Rev Hematol; 2013 Jun; 6(3):229-37. PubMed ID: 23782076
[TBL] [Abstract][Full Text] [Related]
28. How I treat Waldenström macroglobulinemia.
Treon SP
Blood; 2015 Aug; 126(6):721-32. PubMed ID: 26002963
[TBL] [Abstract][Full Text] [Related]
29. Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia.
Guidez S; Labreuche J; Drumez E; Ysebaert L; Bakala J; Delette C; Hivert B; Protin C; Declercq H; Verlay M; Marolleau JP; Duhamel A; Morel P;
Blood Adv; 2018 Nov; 2(22):3102-3111. PubMed ID: 30455359
[TBL] [Abstract][Full Text] [Related]
30. Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia.
Castillo JJ; Meid K; Gustine JN; Dubeau T; Severns P; Hunter ZR; Yang G; Xu L; Treon SP
Clin Cancer Res; 2018 Jul; 24(14):3247-3252. PubMed ID: 29661775
[No Abstract] [Full Text] [Related]
31. International prognostic scoring system for Waldenstrom macroglobulinemia.
Morel P; Duhamel A; Gobbi P; Dimopoulos MA; Dhodapkar MV; McCoy J; Crowley J; Ocio EM; Garcia-Sanz R; Treon SP; Leblond V; Kyle RA; Barlogie B; Merlini G
Blood; 2009 Apr; 113(18):4163-70. PubMed ID: 19196866
[TBL] [Abstract][Full Text] [Related]
32. Fludarabine therapy in Waldenström's macroglobulinemia.
Dimopoulos MA; O'Brien S; Kantarjian H; Pierce S; Delasalle K; Barlogie B; Alexanian R; Keating MJ
Am J Med; 1993 Jul; 95(1):49-52. PubMed ID: 8328496
[TBL] [Abstract][Full Text] [Related]
33. Primary therapy of Waldenström macroglobulinemia with nucleoside analogue-based therapy.
Souchet-Compain L; Nguyen S; Choquet S; Leblond V
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):227-30. PubMed ID: 23531544
[TBL] [Abstract][Full Text] [Related]
34. Waldenström macroglobulinemia.
Vijay A; Gertz MA
Blood; 2007 Jun; 109(12):5096-103. PubMed ID: 17303694
[TBL] [Abstract][Full Text] [Related]
35. Smouldering Waldenstrom's macroglobulinemia: factors predicting evolution to symptomatic disease.
Cesana C; Miqueleiz S; Bernuzzi P; Tresoldi E; Rossi V; D'avanzo G; Filippini D; Morra E
Semin Oncol; 2003 Apr; 30(2):231-5. PubMed ID: 12720142
[TBL] [Abstract][Full Text] [Related]
36. Fludarabine therapy in Waldenström's macroglobulinemia.
Thalhammer-Scherrer R; Geissler K; Schwarzinger I; Chott A; Gisslinger H; Knöbl P; Lechner K; Jäger U
Ann Hematol; 2000 Oct; 79(10):556-9. PubMed ID: 11100745
[TBL] [Abstract][Full Text] [Related]
37. Patterns of survival in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005.
Kristinsson SY; Eloranta S; Dickman PW; Andersson TM; Turesson I; Landgren O; Björkholm M
Am J Hematol; 2013 Jan; 88(1):60-5. PubMed ID: 23165980
[TBL] [Abstract][Full Text] [Related]
38. Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases.
García-Sanz R; Montoto S; Torrequebrada A; de Coca AG; Petit J; Sureda A; Rodríguez-García JA; Massó P; Pérez-Aliaga A; Monteagudo MD; Navarro I; Moreno G; Toledo C; Alonso A; Besses C; Besalduch J; Jarque I; Salama P; Rivas JA; Navarro B; Bladé J; Miguel JF;
Br J Haematol; 2001 Dec; 115(3):575-82. PubMed ID: 11736938
[TBL] [Abstract][Full Text] [Related]
39. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
Dimopoulos MA; García-Sanz R; Gavriatopoulou M; Morel P; Kyrtsonis MC; Michalis E; Kartasis Z; Leleu X; Palladini G; Tedeschi A; Gika D; Merlini G; Kastritis E; Sonneveld P
Blood; 2013 Nov; 122(19):3276-82. PubMed ID: 24004667
[TBL] [Abstract][Full Text] [Related]
40. Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.
Treon SP; Tripsas C; Hanzis C; Ioakimidis L; Patterson CJ; Manning RJ; Sheehy P; Turnbull B; Hunter ZR
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):433-7. PubMed ID: 23084402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
